Skip to main content
SpringerLink
Log in

Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Recently, generic drugs of paclitaxel have been commonly used mainly by economic reasons; however, predictive factors for toxicities are not fully determined. Hypersensitivity reaction (HSR) is one of the most important adverse events in the paclitaxel-based therapy, and sometimes leads to lethal condition. The aim of the study was to identify predictors for HSR in patients treated with paclitaxel-based regimens.

Methods

All the patients treated with chemotherapy including paclitaxel at our hospital between 1998 and 2013 were retrospectively evaluated. Clinicopathological factors of the patients that developed HSR and those without HSR were compared, and predictive factors for HSR were identified.

Results

Among 414 patients enrolled in the study, 26 patients (6.3%) developed HSR. Multivariate analyses showed that younger age (odds ratio 6.31), a history of allergy (odds ratio 3.79), and short-course premedication (odds ratio 14.1) were identified as predictive factors for HSR. There was no significant difference in the incidence of HSR between original paclitaxel and generic drug. The incidence of HSR was higher as the number of these predictors was accumulated.

Conclusions

Three factors were identified as predictive factors for HSR: younger age, a history of allergy, and short-course premedication. Accumulation of these factors increased the incidence of HSR; however, the use of generic drug was not associated HSR in gynecologic cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004–1014

    Article  CAS  PubMed  Google Scholar 

  2. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268

    Article  CAS  PubMed  Google Scholar 

  3. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90:304–305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Grosen E, Siitari E, Larrison E, Tiggelaar C, Roecker E (2000) Paclitaxel hypersensitivity reactions related to bee-sting allergy. Lancet 355:288–289

    Article  CAS  PubMed  Google Scholar 

  5. Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T, Nakano H, Oishi R (2005) Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 56(1):91–96

    Article  CAS  PubMed  Google Scholar 

  6. Piovano E, Pivetta E, Modaffari P, Martra F, Baima Poma C, Perotto S, Tripodi E, Zanfagnin V, Zola P, Ferrero A (2012) A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. Gynecol Obstet Invest 74:21–27

    Article  CAS  PubMed  Google Scholar 

  7. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18:102–105

    Article  CAS  PubMed  Google Scholar 

  8. Lasser EC, Walters A, Reuter SR, Lang J (1971) Histamine release by contrast media. Radiology 100:683–686

    Article  CAS  PubMed  Google Scholar 

  9. Lasser EC, Berry CC, Talner LB, Santini LC, Lang EK, Gerber FH, Stolberg HO (1987) Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 317:845–849

    Article  CAS  PubMed  Google Scholar 

  10. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF (1997) Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8:611–614

    Article  CAS  PubMed  Google Scholar 

  11. Köppler H, Heymanns J, Weide R (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24:283–285

    PubMed  Google Scholar 

  12. Chen W, Mempel M, Schober W, Behrendt H, Ring J (2008) Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy 63:1418–1427

    Article  CAS  PubMed  Google Scholar 

  13. Wolkewitz M, Rothenbacher D, Löw M, Stegmaier C, Ziegler H, Radulescu M, Brenner H, Diepgen TL (2007) Lifetime prevalence of self-reported atopic diseases in a population-based sample of elderly subjects: results of the ESTHER study. Br J Dermatol 156:693–697

    Article  CAS  PubMed  Google Scholar 

  14. Ratanajarusiri T, Sriuranpong V, Sitthideatphaiboon P, Poovoravan N, Vinayanuwat C, Parinyanitikul N, Angspatt P, Thawinwisan W, Tanasanvimon S (2016) A difference in the incidences of hypersensitivity reactions to original and generic taxanes. Chemotherapy 62(2):134–139

    Article  PubMed  Google Scholar 

  15. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17(4):1141

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank MS. Hiromi Kubota for continuous contribution to our clinical study.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

    Tadashi Aoyama, Morikazu Miyamoto, Hiroaki Soyama, Kento Kato, Hiroki Ishibashi, Hideki Iwahashi, Masaya Nakatsuka, Tomoko Goto, Hidenori Sasa & Kenichi Furuya

  2. Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

    Masashi Takano & Tomoyuki Yoshikawa

  3. Department of Host Defense and Biochemical Research, Juntendo University, Graduate School of Medicine, Tokyo, 113-8431, Japan

    Tomoyuki Yoshikawa & Isao Nagaoka

  4. Department of Pharmacy, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

    Isao Yajima, Yukihiro Shimizu & Yusuke Aizawa

  5. Department of Nursing, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan

    Yuki Suguchi & Miki Moriiwa

  6. Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan

    Hitoshi Tsuda

Authors
  1. Tadashi Aoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Morikazu Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoyuki Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroaki Soyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kento Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroki Ishibashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hideki Iwahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masaya Nakatsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Isao Yajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yukihiro Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yusuke Aizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yuki Suguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Miki Moriiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tomoko Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hidenori Sasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Isao Nagaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Hitoshi Tsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Kenichi Furuya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masashi Takano.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

The study protocol was approved by the institutional review board of National Defense Medical College.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 57 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aoyama, T., Takano, M., Miyamoto, M. et al. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?. Cancer Chemother Pharmacol 80, 65–69 (2017). https://doi.org/10.1007/s00280-017-3332-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-017-3332-7

Keywords

Search

Navigation